Published Work Involving WCR Investigators Cited in Later Research
Published ulcerative colitis and obesity studies involving Dr. Lucky Flores and Dr. Gustavo Albizu appear in later research references, including 2026 reviews.
Read more
Dr. Gustavo Albizu Co-Authors Ulcerative Colitis Research Selected for UEG Week 2026
Wellness Clinical Research’s Puerto Rico Principal Investigator is named among the authors of Phase 2a ALTB-268 research scheduled for oral presentation at UEG Week 2026 in Barcelona.
Read more
Dr. Lucky Flores Named Among GRAVITI Investigators in Published Crohn’s Disease Research
Dr. Lucky Flores is listed in the GRAVITI study group for a 2025 Gastroenterology publication evaluating subcutaneous guselkumab in Crohn’s disease.
Read more
Dr. Lucky Flores Listed Among HIBISCUS Investigators in Phase 3 Ulcerative Colitis Research
Dr. Lucky Flores is named in the HIBISCUS study group for published Phase 3 research comparing etrolizumab, adalimumab, and placebo in ulcerative colitis.
Read more
Dr. Lucky Flores Listed Among LUCENT Investigators in NEJM Ulcerative Colitis Publication
Dr. Lucky Flores is listed among LUCENT investigators in the 2023 NEJM publication evaluating mirikizumab for ulcerative colitis.
Read more
Dr. Lucky Flores Listed Among VARSITY Investigators in NEJM Ulcerative Colitis Research
Dr. Lucky Flores is listed among VARSITY investigators in the 2019 NEJM publication comparing vedolizumab and adalimumab in ulcerative colitis.
Read more
FDA Highlights Key Considerations for Digitally Derived Measures in Clinical Investigations
FDA has published a new paper bringing together key considerations for developing and using digitally derived measures as outcomes in clinical investigations, including measures captured through digital health technologies and AI-enabled tools.
Read more
43 Days From Site Selection to First Participant Screened
A recent Phase 2b cardiovascular study at Wellness Clinical Research moved from site selection to activation in 28 days, followed by the first participant screening 15 days later.
Read more
Five Participants Screened by September 3 in Recent Cardiovascular Study
Following the first screening on August 27, the Wellness Clinical Research team screened three additional participants the next day and another on September 3.
Read more
FDA Issues Final Technical Specifications for CGM Data in Clinical Trials
FDA's May 2026 final technical specifications describe how continuous glucose monitoring data should be structured and submitted in clinical trials supporting drug and biologic marketing applications.
Read more
WCR Principal Investigator Dr. Gustavo Albizu Named Among SURMOUNT-5 Trial Investigators
Wellness Clinical Research Principal Investigator Dr. Gustavo Albizu-Angulo is listed among the SURMOUNT-5 Trial Investigators in the New England Journal of Medicine publication comparing tirzepatide and semaglutide for obesity.
Read more
Dr. Lucky Flores Named Among ECOSPOR III and IV Investigators in Published Phase 3 Analysis
Dr. Lucky Flores is named among the ECOSPOR III and ECOSPOR IV investigators in a 2024 peer-reviewed analysis of a microbiome therapeutic for recurrent Clostridioides difficile infection.
Read more
Dr. Gustavo Albizu Named Among SURMOUNT-4 Investigators in JAMA Obesity Trial
Dr. Gustavo R. Albizu-Angulo is listed among the SURMOUNT-4 investigators in the JAMA publication evaluating continued tirzepatide treatment for maintenance of weight reduction in adults with obesity.
Read more
Dr. Lucky Flores and Dr. Gustavo Albizu Featured in Published Phase II Ulcerative Colitis Research
Wellness Clinical Research investigators Dr. Lucky Flores and Dr. Gustavo Albizu-Angulo are listed as authors on published Phase II research evaluating neihulizumab in treatment-refractory ulcerative colitis.
Read more
Dr. Lucky Flores Listed as Investigator in Phase 2 Mirikizumab Crohn’s Disease Research
Dr. Lucky Flores is listed in the investigator supplement for a randomized Phase 2 Gastroenterology study evaluating mirikizumab in patients with moderate-to-severe Crohn’s disease.
Read more
Dr. Lucky Flores Named Among JADE COMPARE Investigators in NEJM Atopic Dermatitis Trial
Dr. Lucky Flores is listed among the JADE COMPARE investigators in the New England Journal of Medicine publication evaluating abrocitinib, dupilumab, and placebo in moderate-to-severe atopic dermatitis.
Read more
Dr. Lucky Flores and Dr. Gustavo Albizu Named Authors on Published Crohn’s Disease Research
Wellness Clinical Research investigators Dr. Lucky Flores and Dr. Gustavo Albizu-Angulo are named authors on a Gastroenterology abstract evaluating ustekinumab in Crohn’s disease with and without concurrent autoimmune skin manifestations.
Read moreConnect with Wellness